An alpha turnaround for Relay
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
Just how independent is Genentech?
Questions continue to swirl as the unit mulls another oncology makeover.
TIGIT blows up in a trial that always looked risky
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
BioNTech claims a FixVac win
But the company hasn’t given details, and used a historical control rather than the study’s own control arm.
Roche’s Skyscraper looks on shaky foundations
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
